Open Access<p>Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer</p>
Author(s) -
Jun Chang,
Hong Ling,
Yaozhong Liu,
Yiwen Pan,
Hao Yang,
Wenrui Ye,
Keli Xu,
Li Z,
Shubing Zhang
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s250171
Subject(s) - in vivo , cancer research , paclitaxel , apoptosis , medicine , pharmacology , chemistry , cancer , biology , biochemistry , microbiology and biotechnology
Molecular targeting is a powerful approach for aggressive claudin-low breast cancer (CLBC). Overexpression of PI3K catalytic subunit gamma (PIK3CG) in human CLBC is offering a promising opportunity for targeted therapies. We utilized a specific inhibitor of PIK3CG combined with paclitaxel (PTX) to treat CLBC cells in vitro and in vivo.